Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus

被引：0
|
作者：
Andreas Maetzel
Jörg Ruof
Melva Covington
Anne Wolf
机构：
[1] University of Toronto,University Health Network Research Institute and Department of Health Policy Management and Evaluation
[2] Hannover Medical School,Health Services Research Unit, Department of Rheumatology, Center of Internal Medicine
[3] Roche Pharmaceuticals,Health Economics Department
[4] Hoffman-La Roche Pharmaceuticals,Medical Outcomes Research and Economics, Medical Science Department
[5] University of Virginia School of Medicine,Department of Health Evaluation Sciences
[6] Toronto General Research Institute,Division of Clinical Decision Making
来源：
PharmacoEconomics | 2003年 / 21卷
关键词：
Metformin; Orlistat; Relative Risk Reduction; Probabilistic Sensitivity Analysis; United Kingdom Prospective Diabetes Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard diabetes therapy and weight management strategies alone in a US-based healthcare setting. The perspective of the study was from the viewpoint of a US healthcare provider.
引用
收藏
页码：501 / 512
页数：11
相关论文
共 50 条
12345